Patient no. | Age | Sex | Grade | Stage | IVI | RT | Size (cm) | Multiplicity | CIS | Recurrence | Progressive disease | Time to progression (months) | Final outcome | Survival time (months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
224 | 87 | M | High | T1 | No | Yes | >3 | No | No | No | M1 | 16 | DOD | 18 |
248 | 66 | M | High | T1 | No | Yes | 1–3 | Yes | No | Yes | T2M1 | 22 | DOD | 41 |
279 | 88 | M | High | T1 | No | No | >3 | Yes | No | Yes | T2 | 7 | DOD | 8 |
284 | 80 | M | High | T1 | M,B | No | >3 | Yes | No | Yes | T2M1 | 21 | DOD | 21 |
348 | 65 | F | High | Ta | B | No | 1–3 | Yes | No | Yes | No | 130* | AW | 130 |
515 | 73 | M | High | T1 | B | Yes | 1–3 | Yes | No | Yes | M1 | 52 | DOD | 57 |
567 | 85 | M | High | T1 | No | No | >3 | Yes | Yes | No | M1 | 4 | DOD | 7 |
658 | 74 | M | High | Ta | B | Yes | 1–3 | Yes | No | Yes | T2 | 33 | DOD | 33 |
711 | 49 | M | High | T1 | M | No | 1–3 | Yes | No | Yes | T4M1 | 10 | DOD | 23 |
715 | 79 | F | High | Ta | M | No | 1–3 | No | Yes | Yes | T3 | 6 | DOD | 7 |
777 | 79 | M | High | T1 | No | No | 1–3 | No | No | No | M1 | 50 | DOD | 50 |
812 | 70 | F | High | Ta | M | No | <1 | Yes | No | Yes | No | 16† | DOO | 16 |
836 | 85 | M | High | Ta | B | No | 1–3 | No | Yes | No | No | 30† | DOO | 30 |
841 | 62 | M | High | Ta | B | No | <1 | Yes | Yes | Yes | No | 53* | AW | 53 |
1105 | 77 | M | High | T1 | No | Yes | 1–3 | No | No | Yes | T2 | 50 | DOD | 59 |
1336 | 65 | M | High | T1 | No | No | >3 | No | No | No | M1 | 5 | DOD | 5 |
*Censored.
†Competing risk.
AW, alive and well; B, Bacille Calmette-Guérin; CIS, carcinoma in situ; DOD, die of the disease; DOO, die of other diseases; IVI, intravesical instillation; M, mitomycin-C; RT, radiotherapy.